Roland Böttger
Senior Research Scientist Ii & Team Lead (Rna Formulation Technology) @Curevac
Signup · Get unlimited contacts
WORK HISTORY
Senior Research Scientist Ii & Team Lead (Rna Formulation Technology) @Curevac
Advanced a prophylactic vaccine into pivotal IND‑enabling (Phase 1 goal) based on a lyophilized mRNA-LNP with superior long‑term storage; secured management approval with robust stability data.(4 patent applications and 2 publications)• Designed LNP compositions and adjuvant approaches to tailor immune profiles by indication, balancing reactogenicity, potency, and durability for infectious disease, oncology, and autoimmunity use applications.• Profiled 10+ external technologies/providers; co‑developed or assessed LNP systems targeting long‑term stability and special administration routes (aerosols, microneedles, oral); evaluated advanced drying techniques.• Initiated out‑licensing negotiations and delivered 10+ international talks at biotech business conferences to support partnering and investor engagement.• Supported R&D → preclinical/CMC alignment, ensuring analytical readiness, comparability criteria, and risk‑based decision gates.
EDUCATION
Leipzig University
Master of Science (M.Sc.), Chemistry
Leipzig University
Dr. rer. nat., Chemistry
Leipzig University
Bachelor of Science (B.Sc.), Chemistry
HHL Leipzig Graduate School of Management
MBA, Business Administration and Management, General
The University of British Columbia
Postdoc, Pharmaceutical Sciences
ABOUT ROLAND BÖTTGER
I’m a Senior Research Scientist II and Team Lead at CureVac, focusing on mRNA-LNP delivery from design and immunogenicity tuning to CMC and translation into IND‑enabling development.What I’ve delivered at CureVac:• Developed a lyophilized mRNA-LNP with superior long‑term storage stability that convinced the company to advance a prophylactic vaccine into pivotal IND‑enabling studies (with a Phase 1 entry goal).• Designed LNPs and adjuvant combinations to shape innate/adaptive responses and optimize immunogenicity across indications; developed advanced drying techniques and assessed special administration routes (aerosols, microneedles, oral).• Profiled 10+ external providers/technologies in parallel; initiated out‑licensing negotiations; delivered 10+ international presentations to support partnering and investor communication.• Contributed 4 patents/patent applications and 2 publications.Alongside my current role, I’m pursuing an MBA at HHL Leipzig (2025–2027) to deepen strategy, leadership, and value creation for scaling RNA platforms from bench → pipeline → partnerships.My background: At UBC, I co‑authored 18 publications (6 first‑author) and 3 patents in nanoformulations; earlier work includes GLP‑1 peptide prodrugs for diabetes, opioid peptides for pain therapy, and antimicrobial peptides. I completed my Dr. rer. nat.(summa cum laude) in Chemisty with 3 first-author publications at Leipzig University.Focus areas: mRNA-LNP design, immunogenicity & adjuvants, stability & lyophilization, analytical/QC for GMP, tech transfer/CMC, external tech scouting, out‑licensing, cross‑functional team leadership.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.